OBJECTIVE: To examine the association of body mass index (BMI) and metabolic status with cognitive function and decline. METHODS: A total of 6,401 adults (71.2% men), aged 39-63 years in 1991-1993, provided data on BMI (normal weight 18.5-24.9 kg/m(2), overweight 25-29.9 kg/m(2); and obese ≥30 kg/m(2)) and metabolic status (abnormality defined as 2 or more of 1) triglycerides ≥1.69 mmol/L or lipid-lowering drugs, 2) systolic blood pressure ≥130 mm Hg, diastolic blood pressure ≥85 mm Hg, or antihypertensive drugs, 3) glucose ≥5.6 mmol/L or medications for diabetes, and 4) high-density lipoprotein cholesterol <1.04 mmol/L for men and <1.29 mmol/L for women). Four cognitive tests (memory, reasoning, semantic, and phonemic fluency) were administered in 1997-1999, 2002-2004, and 2007-2009, standardized to z scores, and averaged to yield a global score. RESULTS: Of the participants, 31.0% had metabolic abnormalities, 52.7% were normal weight, 38.2% were overweight, and 9.1% were obese. Among the obese, the global cognitive score at baseline (p = 0.82) and decline (p = 0.19) over 10 years was similar in the metabolically normal and abnormal groups. In the metabolically normal group, the 10-year decline in the global cognitive score was similar (p for trend = 0.36) in the normal weight (-0.40; 95% confidence interval [CI] -0.42 to -0.38), overweight (-0.42; 95% CI -0.45 to -0.39), and obese (-0.42; 95% CI -0.50 to -0.34) groups. However, in the metabolically abnormal group, the decline on the global score was faster among obese (-0.49; 95% CI -0.55 to -0.42) than among normal weight individuals (-0.42; 95% CI -0.50 to -0.34), (p = 0.03). CONCLUSIONS: In these analyses the fastest cognitive decline was observed in those with both obesity and metabolic abnormality.
OBJECTIVE: To examine the association of body mass index (BMI) and metabolic status with cognitive function and decline. METHODS: A total of 6,401 adults (71.2% men), aged 39-63 years in 1991-1993, provided data on BMI (normal weight 18.5-24.9 kg/m(2), overweight 25-29.9 kg/m(2); and obese ≥30 kg/m(2)) and metabolic status (abnormality defined as 2 or more of 1) triglycerides ≥1.69 mmol/L or lipid-lowering drugs, 2) systolic blood pressure ≥130 mm Hg, diastolic blood pressure ≥85 mm Hg, or antihypertensive drugs, 3) glucose ≥5.6 mmol/L or medications for diabetes, and 4) high-density lipoprotein cholesterol <1.04 mmol/L for men and <1.29 mmol/L for women). Four cognitive tests (memory, reasoning, semantic, and phonemic fluency) were administered in 1997-1999, 2002-2004, and 2007-2009, standardized to z scores, and averaged to yield a global score. RESULTS: Of the participants, 31.0% had metabolic abnormalities, 52.7% were normal weight, 38.2% were overweight, and 9.1% were obese. Among the obese, the global cognitive score at baseline (p = 0.82) and decline (p = 0.19) over 10 years was similar in the metabolically normal and abnormal groups. In the metabolically normal group, the 10-year decline in the global cognitive score was similar (p for trend = 0.36) in the normal weight (-0.40; 95% confidence interval [CI] -0.42 to -0.38), overweight (-0.42; 95% CI -0.45 to -0.39), and obese (-0.42; 95% CI -0.50 to -0.34) groups. However, in the metabolically abnormal group, the decline on the global score was faster among obese (-0.49; 95% CI -0.55 to -0.42) than among normal weight individuals (-0.42; 95% CI -0.50 to -0.34), (p = 0.03). CONCLUSIONS: In these analyses the fastest cognitive decline was observed in those with both obesity and metabolic abnormality.
Authors: Asnawi Abdullah; Rory Wolfe; Johannes U Stoelwinder; Maximilian de Courten; Christopher Stevenson; Helen L Walls; Anna Peeters Journal: Int J Epidemiol Date: 2011-02-27 Impact factor: 7.196
Authors: Gali H Weissberger; Tamar H Gollan; Mark W Bondi; Daniel A Nation; Lawrence A Hansen; Douglas Galasko; David P Salmon Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472
Authors: Mark A Espeland; Stephen R Rapp; George A Bray; Denise K Houston; Karen C Johnson; Abbas E Kitabchi; Andrea L Hergenroeder; Jeff Williamson; John M Jakicic; Brent van Dorsten; Stephen B Kritchevsky Journal: J Gerontol A Biol Sci Med Sci Date: 2014-03-11 Impact factor: 6.053
Authors: Elisa Fabbrini; Jun Yoshino; Mihoko Yoshino; Faidon Magkos; Courtney Tiemann Luecking; Dmitri Samovski; Gemma Fraterrigo; Adewole L Okunade; Bruce W Patterson; Samuel Klein Journal: J Clin Invest Date: 2015-01-02 Impact factor: 14.808
Authors: Erin S LeBlanc; Joanne H Rizzo; Kathryn L Pedula; Kristine Yaffe; Kristine E Ensrud; Jane Cauley; Peggy M Cawthon; Steven Cummings; Teresa A Hillier Journal: J Am Geriatr Soc Date: 2016-12-19 Impact factor: 5.562
Authors: J M Moreno-Navarrete; G Blasco; J Puig; C Biarnés; M Rivero; J Gich; F Fernández-Aranda; J Garre-Olmo; L Ramió-Torrentà; Á Alberich-Bayarri; F García-Castro; S Pedraza; W Ricart; J M Fernández-Real Journal: Int J Obes (Lond) Date: 2017-07-07 Impact factor: 5.095
Authors: Siu Wong; James L Kirkland; Heidi A Schwanz; Amber L Simmons; James A Hamilton; Barbara E Corkey; Wen Guo Journal: Life Sci Date: 2014-05-05 Impact factor: 5.037